2025-12-24 - Analysis Report
Here's an analysis of Merck & Co. Inc. (MRK) based on the provided data, presented in a structured and easily understandable format.

**1. Return Rate Comparison**

*   **Company Overview:** Merck & Co. Inc. (MRK) is a global pharmaceutical company that develops and manufactures a wide range of healthcare products.
*   **MRK Cumulative Return:** 20.30%
*   **S&P 500 (VOO) Cumulative Return:** 100.88%
*   **Divergence:**
    *   Current Divergence: -80.59
    *   Relative Divergence: 18.5
*   **Analysis:** MRK has significantly underperformed the S&P 500 over the analyzed period. The negative divergence indicates that MRK's returns lag considerably behind the market. The relative divergence of 18.5 suggests that the current divergence is relatively closer to the minimum divergence observed than the maximum divergence.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha    | Beta  | Cap(B) |
|------------|---------|---------|----------|-------|--------|
| 2015-2017  | 1.0%    | 68.5%   | -28.0%   | 0.0   | 139.3  |
| 2016-2018  | 36.0%   | 69.8%   | 21.0%    | -0.0  | 189.2  |
| 2017-2019  | 40.0%   | 69.8%   | 18.0%    | 0.3   | 225.2  |
| 2018-2020  | 16.0%   | 79.6%   | -8.0%    | 0.3   | 202.6  |
| 2019-2021  | 2.0%    | 79.6%   | -44.0%   | 0.7   | 198.9  |
| 2020-2022  | 15.0%   | 79.6%   | 16.0%    | 0.7   | 288.0  |
| 2021-2023  | 33.0%   | 79.6%   | 31.0%    | 0.3   | 282.9  |
| 2022-2024  | -4.0%   | 79.6%   | -25.0%   | 0.2   | 258.2  |
| 2023-2025  | -29.0%  | 71.5%   | -94.0%   | 1.8   | 262.4  |

*   **CAGR:** Shows varied annual growth rates, ranging from negative to positive. The recent negative CAGR suggests a downward trend.
*   **MDD:** Consistently high Maximum Drawdown (MDD) indicates significant risk and volatility.
*   **Alpha:** Fluctuates significantly, showing periods of outperformance (positive Alpha) and underperformance (negative Alpha) compared to the benchmark. The recent Alpha is extremely negative, indicating substantial underperformance.
*   **Beta:** Generally low, indicating MRK is less volatile than the overall market, although the most recent Beta is significantly higher.
*   **Cap(B):** Indicates the market capitalization in billions.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 101.09
*   **Last Market Data:** Price: 105.04, Previous Close: 104.72, Change: 0.31
*   **5-day SMA:** 99.90
*   **20-day SMA:** 100.56
*   **60-day SMA:** 91.81
*   **Analysis:** The stock price is currently above its 5-day and 20-day SMAs, suggesting a short-term upward trend. The 20-day SMA is above the 60-day SMA, indicating a potentially positive trend over a slightly longer period. The "Last market data" suggests a recent increase in stock price

**3. Indicator Analysis**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 50.55 (Neutral)
*   **PPO:** -0.49 (Slightly bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** 1.3 (+) Short-term increase
*   **Expected Return (%):** -47.6%
*   **Analysis:**
    *   The MRI suggests a medium level of investment risk.
    *   The RSI indicates a neutral condition, not overbought or oversold.
    *   The PPO is slightly negative, suggesting a minor downward trend in price momentum.
    *   The hybrid signal, despite recommending investment, highlights the "Very Safe" classification.
    *   The negative Expected Return suggests potential underperformance in the long term.

**4. Recent News & Significant Events**

*   **Mixed Headlines:** The news articles present a mixed picture.
    *   Some articles discuss potential drug-pricing bargains and FDA fast-track vouchers, which could be positive.
    *   Others question whether the stock is a buy, even with recent gains.
    *   One article mentions Merck being purchased by Matrix Trust Co, potentially indicating institutional interest.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean of 1.90 on a scale of 1 to 5)
*   **Opinions:** 26 analysts
*   **Target Price:**
    *   Average: 110.04
    *   High: 139.00
    *   Low: 83.00
*   **Recent Rating Changes:** No changes provided.
*   **Analysis:** The analyst consensus is generally positive, with a "Buy" recommendation and a target price significantly above the current price. This suggests analysts anticipate potential upside.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-11-05 | 2.32 | 17.28 B$    |
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2025-11-05 | 1.25 | 16.66 B$    |

*   **Analysis:** The recent EPS and revenue figures show a trend of positive growth in earnings and revenue. The most recent quarter (2025-11-05) shows an increase in EPS and revenue compared to the previous quarters.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $51.85B   | 11.16%|
| 2025-06-30   | $48.99B   | 9.04% |
| 2025-03-31   | $48.34B   | 10.51%|
| 2024-12-31   | $46.31B   | 8.08% |
| 2024-09-30   | $44.50B   | 7.09% |

*   **Analysis:**
    *   **Revenue and Profitability:** Revenues have been increasing steadily in recent quarters, with very high profit margins.
    *   **Capital and Profitability:** Equity is increasing, and Return on Equity (ROE) is improving, reflecting better profitability.

**7. Comprehensive Analysis (Summary)**

*   **Performance:** MRK has significantly underperformed the S&P 500. The Alpha and Beta analysis highlights fluctuating performance and increased risk in recent periods.
*   **Technical Indicators:** Indicators show a mixed picture, with short-term positive price action but a concerning longer-term expected return.
*   **News & Analyst Sentiment:** News articles present a mixed view. However, analysts are generally positive, with a "Buy" rating and higher price targets.
*   **Financials:** Recent earnings and financial data show growth in revenue, high profit margins, increasing equity, and improving ROE.

**Overall Conclusion:**

While recent financial performance and analyst sentiment are positive, the underperformance against the S&P 500 and the negative expected return are concerning. Investors should carefully weigh the positive aspects against these risks. The recent positive momentum in stock price and increasing revenues need to be sustained to justify a strong buy recommendation. The high MDD and recent negative Alpha highlight the need for caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.